Q1 EPS Forecast for Edwards Lifesciences Lowered by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Stock analysts at William Blair lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences in a report released on Tuesday, October 29th. William Blair analyst M. Kaczor now anticipates that the medical research company will earn $0.59 per share for the quarter, down from their previous forecast of $0.64. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.61 per share. William Blair also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.63 EPS, Q3 2025 earnings at $0.61 EPS, Q4 2025 earnings at $0.63 EPS and FY2025 earnings at $2.46 EPS.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the firm earned $0.59 earnings per share. The company’s revenue for the quarter was up 8.9% on a year-over-year basis.

A number of other analysts have also recently weighed in on EW. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Daiwa America raised Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. Truist Financial lowered their price target on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a report on Friday, October 25th. Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. Finally, The Goldman Sachs Group lowered their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Sixteen equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Down 1.1 %

EW stock opened at $68.63 on Wednesday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The firm has a market cap of $41.36 billion, a PE ratio of 29.58, a PEG ratio of 3.00 and a beta of 1.13. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a fifty day simple moving average of $68.07 and a 200 day simple moving average of $77.92.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock worth $1,099,238 over the last quarter. Company insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its position in shares of Edwards Lifesciences by 4.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock worth $31,603,000 after buying an additional 14,087 shares during the period. Empowered Funds LLC raised its position in shares of Edwards Lifesciences by 151.2% during the 1st quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock valued at $1,923,000 after acquiring an additional 12,112 shares during the last quarter. Cetera Advisors LLC lifted its stake in shares of Edwards Lifesciences by 175.1% in the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after purchasing an additional 24,242 shares during the period. Financial Sense Advisors Inc. bought a new position in shares of Edwards Lifesciences in the 1st quarter worth $975,000. Finally, BDF Gestion acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $5,148,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.